Propionibacterium acnes: From Commensal to opportunistic biofilm-associated implant pathogen

Clinical Microbiology Reviews

Volumn 27, Issue 3, 2014, Pages 419-440

  Achermann, Yvonne ^a   Goldstein, Ellie J C ^c,d   Coenye, Tom ^e   Shirtliffa, Mark E ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c R M ALDEN RESEARCH LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; BETA LACTAM; CEFALEXIN; CEFALOTIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; FUSIDIC ACID; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; QUINOLONE; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; UNINDEXED DRUG; VIRULENCE FACTOR;

ACNE VULGARIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BIOFILM; BREAST FIBROSIS; DEVICE INFECTION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; MICROBIOLOGY; NONHUMAN; OSTEOMYELITIS; PHYLOGENY; POLYMERASE CHAIN REACTION; PROPIONIBACTERIUM ACNES; PROSTHESIS INFECTION; SCANNING ELECTRON MICROSCOPY; SEQUENCE ANALYSIS; ULTRASOUND; ANIMAL; CLASSIFICATION; GRAM-POSITIVE BACTERIAL INFECTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METAGENOME; MICROFLORA; PATHOGENICITY; PHYSIOLOGY; PROSTHESES AND ORTHOSES; PROSTHESIS-RELATED INFECTIONS; VIRULENCE;

ANIMALS; BIOFILMS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; METAGENOME; MICROBIOTA; PROPIONIBACTERIUM ACNES; PROSTHESES AND IMPLANTS; PROSTHESIS-RELATED INFECTIONS; VIRULENCE;

EID: 84903558325     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00092-13     Document Type: Article

References (240)

1. Cogen AL, Nizet V, Gallo RL. 2008. Skin microbiota: a source of disease or defence? Br. J. Dermatol. 158:442-455. http://dx.doi.org/10.1111/j.1365-2133.2008.08437.x.
2. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. 2013. The role of intestinal microbiota and the immune system. Eur. Rev. Med. Pharmacol. Sci. 17:323-333.
3. Bojar RA, Holland KT. 2004. Acne and Propionibacterium acnes. Clin. Dermatol. 22:375-379. http://dx.doi.org/10.1016/j.clindermatol.2004.03.005.
4. Moore WE, Cato EP. 1963. Validity of Propionibacterium acnes (Gilchrist) Douglas and Gunter comb. nov. J. Bacteriol. 85:870-874.
5. Williams HC, Dellavalle RP, Garner S. 2012. Acne vulgaris. Lancet 379:361-372. http://dx.doi.org/10.1016/S0140-6736(11)60321-8.
6. Brown SK, Shalita AR. 1998. Acne vulgaris. Lancet 351:1871-1876. http: //dx.doi.org/10.1016/S0140-6736(98)01046-0.
7. Segre JA. 2013. What does it take to satisfy Koch's postulates two centuries later? Microbial genomics and Propionibacteria acnes. J. Investig. Dermatol. 133:2141-2142. http://dx.doi.org/10.1038/jid.2013.260.
8. Fitz-Gibbon S, Tomida S, Chiu BH, Nguyen L, Du C, Liu M, Elashoff D, Erfe MC, Loncaric A, Kim J, Modlin RL, Miller JF, Sodergren E, Craft N, Weinstock GM, Li H. 2013. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J. Investig. Dermatol. 133:2152-2160. http://dx.doi.org/10.1038/jid.2013.21.
9. Shaheen B, Gonzalez M. 2013. Acne sans P. acnes. J. Eur. Acad. Dermatol. Venereol. 27:1-10. http://dx.doi.org/10.1111/j.1468-3083.2012.04516.x.
10. Miura Y, Ishige I, Soejima N, Suzuki Y, Uchida K, Kawana S, Eishi Y. 2010. Quantitative PCR of Propionibacterium acnes DNA in samples aspirated from sebaceous follicles on the normal skin of subjects with or without acne. J. Med. Dent. Sci. 57:65-74.
11. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. 1975. Propionibacterium levels in patients with and without acne vulgaris. J. Investig. Dermatol. 65:382-384. http://dx.doi.org/10.1111/1523-1747.ep12607634.
12. Leyden JJ, McGinley KJ, Vowels B. 1998. Propionibacterium acnes colonization in acne and nonacne. Dermatology 196:55-58. http://dx.doi.org/10.1159/000017868.
13. Leyden JJ. 2001. Current issues in antimicrobial therapy for the treatment of acne. J. Eur. Acad. Dermatol. Venereol. 15(Suppl 3):51-55. http: //dx.doi.org/10.1046/j.0926-9959.2001.00013.x.
14. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. 1983. Propionibacterium acnes resistance to antibiotics in acne patients. J. Am. Acad. Dermatol. 8:41-45. http://dx.doi.org/10.1016/S0190-9622(83)70005-8.
15. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Perez Del Pulgar JI, Rollman O, Torok L, Eady EA, Cove JH. 2003. Antibiotic-resistant acne: lessons from Europe. Br. J. Dermatol. 148:467-478. http://dx.doi.org/10.1046/j.1365-2133.2003.05067.x.
16. Jahns AC, Lundskog B, Ganceviciene R, Palmer RH, Golovleva I, Zouboulis CC, McDowell A, Patrick S, Alexeyev OA. 2012. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br. J. Dermatol. 167:50-58. http://dx.doi.org/10.1111/j.1365-2133.2012.10897.x.
17. Coenye T, Peeters E, Nelis HJ. 2007. Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res. Microbiol. 158:386-392. http://dx.doi.org/10.1016/j.resmic.2007.02.001.
18. Burkhart CN, Burkhart CG. 2003. Microbiology's principle of biofilms as a major factor in the pathogenesis of acne vulgaris. Int. J. Dermatol. 42:925-927. http://dx.doi.org/10.1111/j.1365-4632.2003.01588.x.
19. Alexeyev OA, Lundskog B, Ganceviciene R, Palmer RH, McDowell A, Patrick S, Zouboulis C, Golovleva I. 2012. Pattern of tissue invasion by Propionibacterium acnes in acne vulgaris. J. Dermatol. Sci. 67:63-66. http://dx.doi.org/10.1016/j.jdermsci.2012.03.004.
20. Parsek MR, Singh PK. 2003. Bacterial biofilms: an emerging link to disease pathogenesis. Annu. Rev. Microbiol. 57:677-701. http://dx.doi.org/10.1146/annurev.micro.57.030502.090720.
21. Bayston R, Ashraf W, Barker-Davies R, Tucker E, Clement R, Clayton J, Freeman BJ, Nuradeen B. 2007. Biofilm formation by Propionibacterium acnes on biomaterials in vitro and in vivo: impact on diagnosis and treatment. J. Biomed. Mater. Res. A 81:705-709. http://dx.doi.org/10.1002/jbm.a.31145.
22. Ramage G, Tunney MM, Patrick S, Gorman SP, Nixon JR. 2003. Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials 24:3221-3227. http://dx.doi.org/10.1016/S0142-9612(03)00173-X.
23. Singh JA, Sperling JW, Schleck C, Harmsen W, Cofield RH. 2012. Periprosthetic infections after shoulder hemiarthroplasty. J. Shoulder Elbow Surg. 21:1304-1309. http://dx.doi.org/10.1016/j.jse.2011.08.067.
24. Zeller V, Ghorbani A, Strady C, Leonard P, Mamoudy P, Desplaces N. 2007. Propionibacterium acnes: an agent of prosthetic joint infection and colonization. J. Infect. 55:119-124. http://dx.doi.org/10.1016/j.jinf.2007.02.006.
25. Achermann Y, Sahin F, Schwyzer H, Kolling C, Wust J, Vogt M. 2013. Characteristics and outcome of 16 periprosthetic shoulder joint infections. Infection 41:613-620. http://dx.doi.org/10.1007/s15010-012-0360-4.
26. Levy O, Iyer S, Atoun E, Peter N, Hous N, Cash D, Musa F, Narvani AA. 2013. Propionibacterium acnes: an underestimated etiology in the pathogenesis of osteoarthritis? J. Shoulder Elbow Surg. 22:505-511. http: //dx.doi.org/10.1016/j.jse.2012.07.007.
27. Piper KE, Jacobson MJ, Cofield RH, Sperling JW, Sanchez-Sotelo J, Osmon DR, McDowell A, Patrick S, Steckelberg JM, Mandrekar JN, Fernandez Sampedro M, Patel R. 2009. Microbiologic diagnosis of prosthetic shoulder infection by use of implant sonication. J. Clin. Microbiol. 47:1878-1884. http://dx.doi.org/10.1128/JCM.01686-08.
28. Conen A, Walti LN, Merlo A, Fluckiger U, Battegay M, Trampuz A. 2008. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin. Infect. Dis. 47:73-82. http://dx.doi.org/10.1086 /588298.
29. Walti LN, Conen A, Coward J, Jost GF, Trampuz A. 2013. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J. Infect. 66:424-431. http://dx.doi.org/10.1016/j.jinf.2012.12.010.
30. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ. 2008. Risk factors for infections related to external ventricular drainage. Acta Neurochir. (Wien) 150:209-214. http://dx.doi.org/10.1007/s00701-007-1458-9.
31. Lajcak M, Heidecke V, Haude KH, Rainov NG. 2013. Infection rates of external ventricular drains are reduced by the use of silver-impregnated catheters. Acta Neurochir. (Wien) 155:875-881. http://dx.doi.org/10.1007/s00701-013-1637-9.
32. Rieger UM, Pierer G, Luscher NJ, Trampuz A. 2009. Sonication of removed breast implants for improved detection of subclinical infection. Aesthetic Plast. Surg. 33:404-408. http://dx.doi.org/10.1007/s00266-009-9333-0.
33. Rieger UM, Mesina J, Kalbermatten DF, Haug M, Frey HP, Pico R, Frei R, Pierer G, Luscher NJ, Trampuz A. 2013. Bacterial biofilms and capsular contracture in patients with breast implants. Br. J. Surg. 100: 768-774. http://dx.doi.org/10.1002/bjs.9084.
34. Del Pozo JL, Tran NV, Petty PM, Johnson CH, Walsh MF, Bite U, Clay RP, Mandrekar JN, Piper KE, Steckelberg JM, Patel R. 2009. Pilot study of association of bacteria on breast implants with capsular contracture. J. Clin. Microbiol. 47:1333-1337. http://dx.doi.org/10.1128/JCM.00096-09.
35. Rohacek M, Weisser M, Kobza R, Schoenenberger AW, Pfyffer GE, Frei R, Erne P, Trampuz A. 2010. Bacterial colonization and infection of electrophysiological cardiac devices. Circulation 121:1691-1697. http: //dx.doi.org/10.1161/CIRCULATIONAHA.109.906461.
36. Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, Horowitz HW. 2007. Intravascular device infections: epidemiology, diagnosis, and management. Cardiol. Rev. 15:13-23. http: //dx.doi.org/10.1097/01.crd.0000197966.53529.67.
37. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner S, Baddour LM. 2007. Management and outcome of permanent pacemaker and implantable cardioverterdefibrillator infections. J. Am. Coll. Cardiol. 49:1851-1859. http://dx.doi.org/10.1016/j.jacc.2007.01.072.
38. Brook I, Frazier EH. 1991. Infections caused by Propionibacterium species. Rev. Infect. Dis. 13:819-822. http://dx.doi.org/10.1093/clinids/13.5.819.
39. Patrick S, McDowell A. 2012. The Actinobacteria, part B. Order XII Propionibacteriales ord. nov., p 1137-1155. In Goodfellow M, Kampfer P, Busse H-J, Trujillo M, Suzuki K-I, Ludwig W, Whitman W (ed), Bergey's manual of systematic bacteriology, 2nd ed, vol 5. Springer, New York, NY.
40. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. 2009. Topographical and temporal diversity of the human skin microbiome. Science 324:1190-1192. http://dx.doi.org/10.1126/science.1171700.
41. Grinstead DA, Barefoot SF. 1992. Jenseniin G, a heat-stable bacteriocin produced by Propionibacterium jensenii P126. Appl. Environ. Microbiol. 58:215-220.
42. Patrick S, McDowell A. 2013. Propionibacterium acnes: an emerging pathogen in biomaterial-associated infection, p 87-105. In Moriarty TF (ed), Biomaterials associated infection: immunological aspects and antimicrobial strategies. Springer Science and Business Media, New York, NY.
43. Butler-Wu SM, Burns EM, Pottinger PS, Magaret AS, Rakeman JL, Matsen FA, III, Cookson BT. 2011. Optimization of periprosthetic culture for diagnosis of Propionibacterium acnes prosthetic joint infection. J. Clin. Microbiol. 49:2490-2495. http://dx.doi.org/10.1128/JCM.00450-11.
44. Jousimies-Somer H, Summanen P, Citron D, Baron E, Wexler W, Finegold S. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Co, Belmont, CA.
45. Korting HC, Lukacs A, Vogt N, Urban J, Ehret W, Ruckdeschel G. 1992. Influence of the pH-value on the growth of Staphylococcus epidermidis, Staphylococcus aureus and Propionibacterium acnes in continuous culture. Zentralbl. Hyg. Umweltmed. 193:78-90.
46. Gunthard H, Hany A, Turina M, Wust J. 1994. Propionibacterium acnes as a cause of aggressive aortic valve endocarditis and importance of tissue grinding: case report and review. J. Clin. Microbiol. 32:3043-3045.
47. Schlecht S, Freudenberg MA, Galanos C. 1997. Culture and biological activity of Propionibacterium acnes. Infection 25:247-249. http://dx.doi.org/10.1007/BF01713155.
48. Schafer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L. 2008. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin. Infect. Dis. 47:1403-1409. http://dx.doi.org /10.1086/592973.
49. Larsen LH, Lange J, Xu Y, Schonheyder HC. 2012. Optimizing culture methods for diagnosis of prosthetic joint infections: a summary of modifications and improvements reported since 1995. J. Med. Microbiol. 61:309-316. http://dx.doi.org/10.1099/jmm.0.035303-0.
50. Zappe B, Graf S, Ochsner PE, Zimmerli W, Sendi P. 2008. Propionibacterium spp. in prosthetic joint infections: a diagnostic challenge. Arch. Orthop. Trauma Surg. 128:1039-1046. http://dx.doi.org/10.1007 /s00402-007-0454-0.
51. Patel A, Calfee RP, Plante M, Fischer SA, Green A. 2009. Propionibacterium acnes colonization of the human shoulder. J. Shoulder Elbow Surg. 18:897-902. http://dx.doi.org/10.1016/j.jse.2009.01.023.
52. Levy PY, Fenollar F, Stein A, Borrione F, Cohen E, Lebail B, Raoult D. 2008. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin. Infect. Dis. 46:1884-1886. http://dx.doi.org/10.1086/588477.
53. Brüggemann H, Henne A, Hoster F, Liesegang H, Wiezer A, Strittmatter A, Hujer S, Durre P, Gottschalk G. 2004. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 305:671-673. http://dx.doi.org/10.1126/science.1100330.
54. McDowell A, Valanne S, Ramage G, Tunney MM, Glenn JV, McLorinan GC, Bhatia A, Maisonneuve JF, Lodes M, Persing DH, Patrick S. 2005. Propionibacterium acnes types I and II represent phylogenetically distinct groups. J. Clin. Microbiol. 43:326-334. http://dx.doi.org/10.1128/JCM.43.1.326-334.2005.
55. McDowell A, Perry AL, Lambert PA, Patrick S. 2008. A new phylogenetic group of Propionibacterium acnes. J. Med. Microbiol. 57:218-224. http://dx.doi.org/10.1099/jmm.0.47489-0.
56. Valanne S, McDowell A, Ramage G, Tunney MM, Einarsson GG, O'Hagan S, Wisdom GB, Fairley D, Bhatia A, Maisonneuve JF, Lodes M, Persing DH, Patrick S. 2005. CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology 151:1369-1379. http://dx.doi.org/10.1099/mic.0.27788-0.
57. McDowell A, Gao A, Barnard E, Fink C, Murray PI, Dowson CG, Nagy I, Lambert PA, Patrick S. 2011. A novel multilocus sequence typing scheme for the opportunistic pathogen Propionibacterium acnes and characterization of type I cell surface-associated antigens. Microbiology 157:1990-2003. http://dx.doi.org/10.1099/mic.0.049676-0.
58. Lomholt HB, Kilian M. 2010. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One 5:e12277. http://dx.doi.org/10.1371/journal.pone.0012277.
59. Lodes MJ, Secrist H, Benson DR, Jen S, Shanebeck KD, Guderian J, Maisonneuve JF, Bhatia A, Persing D, Patrick S, Skeiky YA. 2006. Variable expression of immunoreactive surface proteins of Propionibacterium acnes. Microbiology 152:3667-3681. http://dx.doi.org/10.1099 /mic.0.29219-0.
60. Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A, Seltmann H, Patrick S, Zouboulis CC, Kemeny L. 2006. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 8:2195-2205. http://dx.doi.org/10.1016/j.micinf.2006.04.001.
61. McDowell A, Barnard E, Nagy I, Gao A, Tomida S, Li H, Eady A, Cove J, Nord CE, Patrick S. 2012. An expanded multilocus sequence typing scheme for Propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains. PLoS One 7:e41480. http://dx.doi.org/10.1371/journal.pone.0041480.
62. Sampedro MF, Piper KE, McDowell A, Patrick S, Mandrekar JN, Rouse MS, Steckelberg JM, Patel R. 2009. Species of Propionibacterium and Propionibacterium acnes phylotypes associated with orthopedic implants. Diagn. Microbiol. Infect. Dis. 64:138-145. http://dx.doi.org/10.1016/j.diagmicrobio.2009.01.024.
63. McDowell A, Hunyadkurti J, Horvath B, Voros A, Barnard E, Patrick S, Nagy I. 2012. Draft genome sequence of an antibiotic-resistant Propionibacterium acnes strain, PRP-38, from the novel type IC cluster. J. Bacteriol. 194:3260-3261. http://dx.doi.org/10.1128/JB.00479-12.
64. McDowell A, Nagy I, Magyari M, Barnard E, Patrick S. 2013. The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLoS One 8:e70897. http://dx.doi.org/10.1371/journal.pone.0070897.
65. Brüggemann H. 2005. Insights in the pathogenic potential of Propionibacterium acnes from its complete genome. Semin. Cutan. Med. Surg. 24:67-72. http://dx.doi.org/10.1016/j.sder.2005.03.001.
66. Nakatsuji T, Tang DC, Zhang L, Gallo RL, Huang CM. 2011. Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One 6:e14797. http://dx.doi.org/10.1371/journal.pone.0014797.
67. Choudhury TK. 1978. Synergistic lysis of erythrocytes by Propionibacterium acnes. J. Clin. Microbiol. 8:238-241.
68. Brzuszkiewicz E, Weiner J, Wollherr A, Thurmer A, Hupeden J, Lomholt HB, Kilian M, Gottschalk G, Daniel R, Mollenkopf HJ, Meyer TF, Brüggemann H. 2011. Comparative genomics and transcriptomics of Propionibacterium acnes. PLoS One 6:e21581. http://dx.doi.org /10.1371/journal.pone.0021581.
69. Holland C, Mak TN, Zimny-Arndt U, Schmid M, Meyer TF, Jungblut PR, Brüggemann H. 2010. Proteomic identification of secreted proteins of Propionibacterium acnes. BMCMicrobiol. 10:230. http://dx.doi.org/10.1186/1471-2180-10-230.
70. Holmberg A, Lood R, Mörgelin M, Söderquist B, Holst E, Collin M, Christensson B, Rasmussen M. 2009. Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clin. Microbiol. Infect. 15:787-795. http://dx.doi.org/10.1111/j.1469-0691.2009.02747.x.
71. Gallo J, Kolar M, Novotny R, Rihakova P, Ticha V. 2003. Pathogenesis of prosthesis-related infection. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 147:27-35. http://dx.doi.org/10.5507/bp.2003.004.
72. Johnston DH, Fairclough JA, Brown EM, Morris R. 1987. Rate of bacterial recolonization of the skin after preparation: four methods compared. Br. J. Surg. 74:64. http://dx.doi.org/10.1002/bjs.1800740121.
73. Clayton JJ, Baig W, Reynolds GW, Sandoe JA. 2006. Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties. J. Med. Microbiol. 55:981-987. http://dx.doi.org/10.1099/jmm.0.46613-0.
74. Sohail MR, Gray AL, Baddour LM, Tleyjeh IM, Virk A. 2009. Infective endocarditis due to Propionibacterium species. Clin. Microbiol. Infect. 15:387-394. http://dx.doi.org/10.1111/j.1469-0691.2009.02703.x.
75. Gristina AG, Naylor P, Myrvik Q. 1988. Infections from biomaterials and implants: a race for the surface. Med. Prog. Technol. 14:205-224.
76. Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A, Dreno B. 2005. Induction of Toll-like receptors by Propionibacterium acnes. Br. J. Dermatol. 153:1105-1113. http://dx.doi.org/10.1111/j.1365-2133.2005.06933.x.
77. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. 2002. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. 169:1535-1541. http: //www.jimmunol.org/content/169/3/1535.long.
78. Kamisango K, Fujii H, Okumura H, Saiki I, Araki Y, Yamamura Y, Azuma I. 1983. Structural and immunochemical studies of teichoic acid of Listeria monocytogenes. J. Biochem. 93:1401-1409.
79. Burkhart CG, Burkhart CN, Lehmann PF. 1999. Acne: a review of immunologic and microbiologic factors. Postgrad. Med. J. 75:328-331.
80. Kalis C, Gumenscheimer M, Freudenberg N, Tchaptchet S, Fejer G, Heit A, Akira S, Galanos C, Freudenberg MA. 2005. Requirement for TLR9 in the immunomodulatory activity of Propionibacterium acnes. J. Immunol. 174:4295-4300. http://www.jimmunol.org/content/174/7/42 95.long.
81. Tchaptchet S, Gumenscheimer M, Kalis C, Freudenberg N, Holscher C, Kirschning CJ, Lamers M, Galanos C, Freudenberg MA. 2012. TLR9-dependent and independent pathways drive activation of the immune system by Propionibacterium acnes. PLoS One 7:e39155. http://dx.doi.org/10.1371/journal.pone.0039155.
82. Nakatsuji T, Shi Y, Zhu W, Huang CP, Chen YR, Lee DY, Smith JW, Zouboulis CC, Gallo RL, Huang CM. 2008. Bioengineering a humanized acne microenvironment model: proteomics analysis of host responses to Propionibacterium acnes infection in vivo. Proteomics 8:3406-3415. http://dx.doi.org/10.1002/pmic.200800044.
83. Knor T. 2005. The pathogenesis of acne. Acta Dermatovenerol. Croat. 13:44-49.
84. Dessinioti C, Katsambas AD. 2010. The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clin. Dermatol. 28:2-7. http://dx.doi.org/10.1016/j.clindermatol.2009.03.012.
85. Holland DB, Ingham E, Gowland G, Cunliffe WJ. 1986. IgG subclasses in acne vulgaris. Br. J. Dermatol. 114:349-351. http://dx.doi.org/10.1111 /j.1365-2133.1986.tb02826.x.
86. Ingham E, Gowland G, Ward RM, Holland KT, Cunliffe WJ. 1987. Antibodies to P. acnes and P. acnes exocellular enzymes in the normal population at various ages and in patients with acne vulgaris. Br. J. Dermatol. 116:805-812. http://dx.doi.org/10.1111/j.1365-2133.1987.tb04899.x.
87. Webster GF, Leyden JJ, Musson RA, Douglas SD. 1985. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect. Immun. 49:116-121.
88. Csukas Z, Banizs B, Rozgonyi F. 2004. Studies on the cytotoxic effects of Propionibacterium acnes strains isolated from cornea. Microb. Pathog. 36:171-174. http://dx.doi.org/10.1016/j.micpath.2003.09.002.
89. Fischer N, Mak TN, Shinohara DB, Sfanos KS, Meyer TF, Brüggemann H. 2013. Deciphering the intracellular fate of Propionibacterium acnes in macrophages. Biomed. Res. Int. 2013:603046. http://dx.doi.org /10.1155/2013/603046.
90. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. 2011. Staphylococcus aureus biofilms: properties, regulation, and roles in human. Virulence 2:445-459. http://dx.doi.org/10.4161/viru.2.5.17724.
91. Dunne WM, Jr. 2002. Bacterial adhesion: seen any good biofilms lately? Clin. Microbiol. Rev. 15:155-166. http://dx.doi.org/10.1128/CMR.15.2.155-166.2002.
92. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http: //dx.doi.org/10.1126/science.284.5418.1318.
93. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497. http://dx.doi.org/10.1093 /infdis/146.4.487.
94. Zimmerli W, Lew PD, Waldvogel FA. 1984. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J. Clin. Invest. 73:1191-1200.
95. Kristian SA, Birkenstock TA, Sauder U, Mack D, Gotz F, Landmann R. 2008. Biofilm formation induces C3a release and protects Staphylococcus epidermidis. J. Infect. Dis. 197:1028-1035. http://dx.doi.org/10.1086/528992.
96. Leid JG, Shirtliff ME, Costerton JW, Stoodley P. 2002. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect. Immun. 70:6339-6345. http://dx.doi.org/10.1128/IAI.70.11.6339-6345.2002.
97. Prabhakara R, Harro JM, Leid JG, Keegan AD, Prior ML, Shirtliff ME. 2011. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun. 79:5010-5018. http://dx.doi.org /10.1128/IAI.05571-11.
98. Alhede M, Bjarnsholt T, Jensen PO, Phipps RK, Moser C, Christophersen L, Christensen LD, van Gennip M, Parsek M, Hoiby N, Rasmussen TB, Givskov M. 2009. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology 155:3500-3508. http://dx.doi.org/10.1099/mic.0.031443-0.
99. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Hoiby N, Givskov M. 2005. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorumsensing dependent. Microbiology 151:373-383. http://dx.doi.org/10.1099/mic.0.27463-0.
100. Jensen PO, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L, Moser C, Williams P, Pressler T, Givskov M, Hoiby N. 2007. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153:1329-1338. http://dx.doi.org /10.1099/mic.0.2006/003863-0.
101. van Gennip M, Christensen LD, Alhede M, Qvortrup K, Jensen PO, Hoiby N, Givskov M, Bjarnsholt T. 2012. Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo. Infect. Immun. 80:2601-2607. http://dx.doi.org /10.1128/IAI.06215-11.
102. Van Gennip M, Christensen LD, Alhede M, Phipps R, Jensen PO, Christophersen L, Pamp SJ, Moser C, Mikkelsen PJ, Koh AY, Tolker-Nielsen T, Pier GB, Hoiby N, Givskov M, Bjarnsholt T. 2009. Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS 117:537-546. http://dx.doi.org/10.1111/j.1600-0463.2009.02466.x.
103. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
104. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654. http://dx.doi.org/10.1056 /NEJMra040181.
105. Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. 2012. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 56:1885-1891. http://dx.doi.org/10.1128/AAC.05552-11.
106. Mack D, Haeder M, Siemssen N, Laufs R. 1996. Association of biofilm production of coagulase-negative staphylococci with expression of a specific polysaccharide intercellular adhesin. J. Infect. Dis. 174:881-884. http://dx.doi.org/10.1093/infdis/174.4.881.
107. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, Scherpe S, Davies AP, Harris LG, Horstkotte MA, Knobloch JK, Ragunath C, Kaplan JB, Mack D. 2007. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation. Biomaterials 28: 1711-1720. http://dx.doi.org/10.1016/j.biomaterials.2006.11.046.
108. Qi X, Gao J, Sun D, Liang W, Wan Y, Li C, Xu X, Gao T. 2008. Biofilm formation of the pathogens of fatal bacterial granuloma after trauma. Scand. J. Infect. Dis. 40:221-228. http://dx.doi.org/10.1080/0036554070 1632998.
109. Tunney MM, Patrick S, Curran MD, Ramage G, Hanna D, Nixon JR, Gorman SP, Davis RI, Anderson N. 1999. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J. Clin. Microbiol. 37:3281-3290.
110. Herrmann M, Vaudaux PE, Pittet D, Auckenthaler R, Lew PD, Schumacher-Perdreau F, Peters G, Waldvogel FA. 1988. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J. Infect. Dis. 158:693-701. http://dx.doi.org/10.1093/infdis/158.4.693.
111. Yu JL, Mansson R, Flock JI, Ljungh A. 1997. Fibronectin binding by Propionibacterium acnes. FEMS Immunol. Med. Microbiol. 19:247-253. http://dx.doi.org/10.1111/j.1574-695X.1997.tb01094.x.
112. Whale GA, Sutcliffe IC, Morrisson AR, Pretswell EL, Emmison N. 2004. Purification and characterisation of lipoglycan macroamphiphiles from Propionibacterium acnes. Antonie Van Leeuwenhoek 86:77-85. http://dx.doi.org/10.1023/B:ANTO.0000024911.67625.27.
113. Lee WL, Shalita AR, Suntharalingam K, Fikrig SM. 1982. Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition. Infect. Immun. 35:71-78.
114. Blomgren G, Lundquist H, Nord CE, Lindgren U. 1981. Late anaerobic haematogenous infection of experimental total joint replacement. A study in the rabbit using Propionibacterium acnes. J. Bone Joint Surg. Br. 63B:614-618.
115. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. 2012. Economic burden of periprosthetic joint infection in the United States. J. Arthroplasty 27:61-65. e61. http://dx.doi.org/10.1016/j.arth.2012.02.022.
116. Achermann Y, Vogt M, Leunig M, Wust J, Trampuz A. 2010. Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fluid from removed implants. J. Clin. Microbiol. 48:1208-1214. http://dx.doi.org/10.1128/JCM.00006-10.
117. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, Mandrekar JN, Cockerill FR, Steckelberg JM, Greenleaf JF, Patel R. 2007. Sonication of removed hip and knee prostheses for diagnosis of infection. N. Engl. J. Med. 357:654-663. http://dx.doi.org/10.1056 /NEJMoa061588.
118. Vergidis P, Greenwood-Quaintance KE, Sanchez-Sotelo J, Morrey BF, Steinmann SP, Karau MJ, Osmon DR, Mandrekar JN, Steckelberg JM, Patel R. 2011. Implant sonication for the diagnosis of prosthetic elbow infection. J. Shoulder Elbow Surg. 20:1275-1281. http://dx.doi.org/10.1016/j.jse.2011.06.016.
119. Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R. 2003. Molecular and antibiofilm approaches to prosthetic joint infection. Clin. Orthop. Relat. Res. 2003:69-88. http://dx.doi.org/10.1097/01.blo.0000087324.60612.93.
120. Marin M, Garcia-Lechuz JM, Alonso P, Villanueva M, Alcala L, Gimeno M, Cercenado E, Sanchez-Somolinos M, Radice C, Bouza E. 2012. Role of universal 16S rRNA gene PCR and sequencing in diagnosis of prosthetic joint infection. J. Clin. Microbiol. 50:583-589. http://dx.doi.org/10.1128/JCM.00170-11.
121. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. 2013. Diagnosis and management of prosthetic joint infection: clinical practice. Clin. Infect. Dis. 56:e1-e25. http://dx.doi.org/10.1093/cid/cis803.
122. Wang B, Toye B, Desjardins M, Lapner P, Lee C. 2013. A 7-year retrospective review from 2005 to 2011 of Propionibacterium acnes shoulder infections in Ottawa, Ontario, Canada. Diagn. Microbiol. Infect. Dis. 75:195-199. http://dx.doi.org/10.1016/j.diagmicrobio.2012.10.018.
123. Cheung EV, Sperling JW, Cofield RH. 2008. Infection associated with hematoma formation after shoulder arthroplasty. Clin. Orthop. Relat. Res. 466:1363-1367. http://dx.doi.org/10.1007/s11999-008-0226-3.
124. Coste JS, Reig S, Trojani C, Berg M, Walch G, Boileau P. 2004. The management of infection in arthroplasty of the shoulder. J. Bone Joint Surg. Br. 86:65-69. http://www.bjj.boneandjoint.org.uk/content/86-B/1 /65.long.
125. Grosso MJ, Sabesan VJ, Ho JC, Ricchetti ET, Iannotti JP. 2012. Reinfection rates after 1-stage revision shoulder arthroplasty for patients with unexpected positive intraoperative cultures. J. Shoulder Elbow Surg. 21:754-758. http://dx.doi.org/10.1016/j.jse.2011.08.052.
126. Ince A, Seemann K, Frommelt L, Katzer A, Loehr JF. 2005. One-stage exchange shoulder arthroplasty for peri-prosthetic infection. J. Bone Joint Surg. Br. 87:814-818. http://www.bjj.boneandjoint.org.uk /content/87-B/6/814.long.
127. Kanafani ZA, Sexton DJ, Pien BC, Varkey J, Basmania C, Kaye KS. 2009. Postoperative joint infections due to Propionibacterium species: a case-control study. Clin. Infect. Dis. 49:1083-1085. http://dx.doi.org/10.1086/605577.
128. Pottinger P, Butler-Wu S, Neradilek MB, Merritt A, Bertelsen A, Jette JL, Warme WJ, Matsen FA, III. 2012. Prognostic factors for bacterial cultures positive for Propionibacterium acnes and other organisms in a large series of revision shoulder arthroplasties performed for stiffness, pain, or loosening. J. Bone Joint Surg. Am. 94:2075-2083. http://dx.doi.org/10.2106/JBJS.K.00861.
129. Stevens WG, Nahabedian MY, Calobrace MB, Harrington JL, Capizzi PJ, Cohen R, d'Incelli RC, Beckstrand M. 2013. Risk factor analysis for capsular contracture: a five-year Sientra study analysis using round, smooth and textured implants for breast augmentation. Plast. Reconstr. Surg. 132:1115-1123. http://dx.doi.org/10.1097/01.prs.0000435317.76381.68.
130. Ersek RA. 1991. Rate and incidence of capsular contracture: a comparison of smooth and textured silicone double-lumen breast prostheses. Plast. Reconstr. Surg. 87:879-884. http://dx.doi.org/10.1097/00006534-199105000-00012.
131. Braun DL, Hasse BK, Stricker J, Fehr JS. 2013. Prosthetic valve endocarditis caused by Propionibacterium species successfully treated with coadministered rifampin: report of two cases. BMJ Case Rep. 2013: bcr2012007204. http://dx.doi.org/10.1136/bcr-2012-007204.
132. Noel W, Hammoudi N, Wegorowska E, D'Alessandro C, Steichen O. 2012. Pacemaker endocarditis caused by Propionibacterium acnes: a case report. Heart Lung 41:e21-e23. http://dx.doi.org/10.1016/j.hrtlng.2012.04.006.
133. Delahaye F, Fol S, Celard M, Vandenesch F, Beaune J, Bozio A, de Gevigney G. 2005. Propionibacterium acnes infective endocarditis. Study of 11 cases and review of literature. Arch. Mal. Coeur Vaiss. 98:1212-1218. (In French.)
134. Park HJ, Na S, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Lee SO, Kim YS, Woo JH, Kim MN, Choi SH. 2011. Clinical significance of Propionibacterium acnes recovered from blood cultures: analysis of 524 episodes. J. Clin. Microbiol. 49:1598-1601. http://dx.doi.org/10.1128/JCM.01842-10.
135. Zimmerli W. 2010. Vertebral osteomyelitis. N. Engl. J. Med. 362:1022-1029. http://dx.doi.org/10.1056/NEJMcp0910753.
136. Sampedro MF, Huddleston PM, Piper KE, Karau MJ, Dekutoski MB, Yaszemski MJ, Currier BL, Mandrekar JN, Osmon DR, McDowell A, Patrick S, Steckelberg JM, Patel R. 2010. A biofilm approach to detect bacteria on removed spinal implants. Spine 35:1218-1224. http://dx.doi.org/10.1097/BRS.0b013e3181c3b2f3.
137. Kowalski TJ, Berbari EF, Huddleston PM, Steckelberg JM, Osmon DR. 2007. Propionibacterium acnes vertebral osteomyelitis: seek and ye shall find? Clin. Orthop. Relat. Res. 461:25-30.
138. Haidar R, Najjar M, Der Boghossian A, Tabbarah Z. 2010. Propionibacterium acnes causing delayed postoperative spine infection: review. Scand. J. Infect. Dis. 42:405-411. http://dx.doi.org/10.3109/0036554090 3582459.
139. Hahn F, Zbinden R, Min K. 2005. Late implant infections caused by Propionibacterium acnes in scoliosis surgery. Eur. Spine J. 14:783-788. http://dx.doi.org/10.1007/s00586-004-0854-6.
140. Uckay I, Dinh A, Vauthey L, Asseray N, Passuti N, Rottman M, Biziragusenyuka J, Riche A, Rohner P, Wendling D, Mammou S, Stern R, Hoffmeyer P, Bernard L. 2010. Spondylodiscitis due to Propionibacterium acnes: report of twenty-nine cases and a review of the literature. Clin. Microbiol. Infect. 16:353-358. http://dx.doi.org/10.1111/j.1469-0691.2009.02801.x.
141. Lutz JA, Otten P, Maestretti G. 2012. Late infections after dynamic stabilization of the lumbar spine with Dynesys. Eur. Spine J. 21:2573-2579. http://dx.doi.org/10.1007/s00586-012-2366-0.
142. Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TS. 2001. Association between sciatica and Propionibacterium acnes. Lancet 357: 2024-2025. http://dx.doi.org/10.1016/S0140-6736(00)05109-6.
143. Albert HB, Lambert P, Rollason J, Sorensen JS, Worthington T, Pedersen MB, Norgaard HS, Vernallis A, Busch F, Manniche C, Elliott T. 2013. Does nuclear tissue infected with bacteria following disc herniations lead to Modic changes in the adjacent vertebrae? Eur. Spine J. 22:690-696. http://dx.doi.org/10.1007/s00586-013-2674-z.
144. Albert HB, Sorensen JS, Christensen BS, Manniche C. 2013. Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy. Eur. Spine J. 22:697-707. http://dx.doi.org/10.1007/s00586-013-2675-y.
145. McHenry MC, Easley KA, Locker GA. 2002. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin. Infect. Dis. 34:1342-1350. http://dx.doi.org/10.1086/340102.
146. Jakab E, Zbinden R, Gubler J, Ruef C, von Graevenitz A, Krause M. 1996. Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J. Biol. Med. 69: 477-482.
147. Richards BR, Emara KM. 2001. Delayed infections after posterior TSRH spinal instrumentation for idiopathic scoliosis: revisited. Spine 26:1990-1996. http://dx.doi.org/10.1097/00007632-200109150-00009.
148. Rao SB, Vasquez G, Harrop J, Maltenfort M, Stein N, Kaliyadan G, Klibert F, Epstein R, Sharan A, Vaccaro A, Flomenberg P. 2011. Risk factors for surgical site infections following spinal fusion procedures: a case-control study. Clin. Infect. Dis. 53:686-692. http://dx.doi.org/10.1093/cid/cir506.
149. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. 2013. Executive summary: diagnosis and management of prosthetic joint infection. Clin. Infect. Dis. 56:1-10. http://dx.doi.org/10.1093/cid/cis966.
150. Parvizi J, Della Valle CJ. 2010. AAOS clinical practice guideline: diagnosis and treatment of periprosthetic joint infections of the hip and knee. J. Am. Acad. Orthop. Surg. 18:771-772.
151. Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE, McLardy-Smith P, Berendt AR. 1998. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. J. Clin. Microbiol. 36:2932-2939.
152. Font-Vizcarra L, Garcia S, Martinez-Pastor JC, Sierra JM, Soriano A. 2010. Blood culture flasks for culturing synovial fluid in prosthetic joint infections. Clin. Orthop. Relat. Res. 468:2238-2243. http://dx.doi.org/10.1007/s11999-010-1254-3.
153. Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R. 2004. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. Am. J. Med. 117:556-562. http: //dx.doi.org/10.1016/j.amjmed.2004.06.022.
154. Tunney MM, Patrick S, Gorman SP, Nixon JR, Anderson N, Davis RI, Hanna D, Ramage G. 1998. Improved detection of infection in hip replacements. A currently underestimated problem. J. Bone Joint Surg. Br. 80:568-572.
155. Trampuz A, Steinhuber A, Wittwer M, Leib SL. 2007. Rapid diagnosis of experimental meningitis by bacterial heat production in cerebrospinal fluid. BMC Infect. Dis. 7:116. http://dx.doi.org/10.1186/1471-2334-7-116.
156. Portillo ME, Salvado M, Trampuz A, Plasencia V, Rodriguez-Villasante M, Sorli L, Puig L, Horcajada JP. 2013. Sonication versus vortexing of implants for diagnosis of prosthetic joint infection. J. Clin. Microbiol. 51:591-594. http://dx.doi.org/10.1128/JCM.02482-12.
157. Monsen T, Lövgren E, Widerström M, Wallinder L. 2009. In vitro effect of ultrasound on bacteria and suggested protocol for sonication and diagnosis of prosthetic infections. J. Clin. Microbiol. 47:2496-2501. http://dx.doi.org/10.1128/JCM.02316-08.
158. Bonkat G, Rieken M, Rentsch CA, Wyler S, Feike A, Schafer J, Gasser T, Trampuz A, Bachmann A, Widmer AF. 2011. Improved detection of microbial ureteral stent colonisation by sonication. World J. Urol. 29: 133-138. http://dx.doi.org/10.1007/s00345-010-0535-5.
159. Sfanos KS, Isaacs WB. 2008. An evaluation of PCR primer sets used for detection of Propionibacterium acnes in prostate tissue samples. Prostate 68:1492-1495. http://dx.doi.org/10.1002/pros.20820.
160. Alexeyev OA, Marklund I, Shannon B, Golovleva I, Olsson J, Andersson C, Eriksson I, Cohen R, Elgh F. 2007. Direct visualization of Propionibacterium acnes in prostate tissue by multicolor fluorescent in situ hybridization assay. J. Clin. Microbiol. 45:3721-3728. http://dx.doi.org/10.1128/JCM.01543-07.
161. Yamada T, Eishi Y, Ikeda S, Ishige I, Suzuki T, Takemura T, Takizawa T, Koike M. 2002. In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J. Pathol. 198:541-547. http://dx.doi.org/10.1002/path.1243.
162. Poppert S, Riecker M, Essig A. 2010. Rapid identification of Propionibacterium acnes from blood cultures by fluorescence in situ hybridization. Diagn. Microbiol. Infect. Dis. 66:214-216. http://dx.doi.org/10.1016/j.diagmicrobio.2009.09.007.
163. Illingworth KD, Mihalko WM, Parvizi J, Sculco T, McArthur B, el Bitar Y, Saleh KJ. 2013. How to minimize infection and thereby maximize patient outcomes in total joint arthroplasty: a multicenter approach. AAOS exhibit selection. J. Bone Joint Surg. Am. 95:e50. http://dx.doi.org/10.2106/JBJS.L.00596.
164. Nakatsuji T, Liu YT, Huang CP, Zouboulis CC, Gallo RL, Huang CM. 2008. Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. PLoS One 3:e1551. http://dx.doi.org/10.1371/journal.pone.0001551.
165. Liu PF, Nakatsuji T, Zhu W, Gallo RL, Huang CM. 2011. Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine 29: 3230-3238. http://dx.doi.org/10.1016/j.vaccine.2011.02.036.
166. Crane JK, Hohman DW, Nodzo SR, Duquin TR. 2013. Antimicrobial susceptibility of Propionibacterium acnes isolates from shoulder surgery. Antimicrob. Agents Chemother. 57:3424-3426. http://dx.doi.org/10.1128/AAC.00463-13.
167. Oprica C, Nord CE. 2005. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin. Microbiol. Infect. 11: 204-213. http://dx.doi.org/10.1111/j.1469-0691.2004.01055.x.
168. Denys GA, Jerris RC, Swenson JM, Thornsberry C. 1983. Susceptibility of Propionibacterium acnes clinical isolates to 22 antimicrobial agents. Antimicrob. Agents Chemother. 23:335-337. http://dx.doi.org/10.1128 /AAC.23.2.335.
169. Leyden JJ. 1976. Antibiotic resistant acne. Cutis 17:593-596.
170. Crawford WW, Crawford IP, Stoughton RB, Cornell RC. 1979. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J. Investig. Dermatol. 72:187-190. http://dx.doi.org/10.1111/1523-1747.ep12676385.
171. Nakase K, Nakaminami H, Noguchi N, Nishijima S, Sasatsu M. 2012. First report of high levels of clindamycin-resistant Propionibacterium acnes carrying erm(X) in Japanese patients with acne vulgaris. J. Dermatol. 39:794-796. http://dx.doi.org/10.1111/j.1346-8138.2011.01423.x.
172. Moon SH, Roh HS, Kim YH, Kim JE, Ko JY, Ro YS. 2012. Antibiotic resistance of microbial strains isolated from Korean acne patients. J. Dermatol. 39:833-837. http://dx.doi.org/10.1111/j.1346-8138.2012.01626.x.
173. Cooper AJ. 1998. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med. J. Aust. 169:259-261.
174. Schafer F, Fich F, Lam M, Garate C, Wozniak A, Garcia P. 2013. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int. J. Dermatol. 52:418-425. http://dx.doi.org/10.1111/j.1365-4632.2011.05371.x.
175. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 8th ed. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
176. European Committee on Antimicrobial Susceptibility Testing. 2010. Setting breakpoints for existing antimicrobial agents. EUCAST SOP 2.0. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden.
177. Brook I, Wexler HM, Goldstein EJ. 2013. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin. Microbiol. Rev. 26:526-546. http://dx.doi.org/10.1128/CMR.00086-12.
178. Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, Collignon P, Dreno B, Reynaud A, Fluhr J, Oshima S. 2001. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br. J. Dermatol. 144:339-346. http://dx.doi.org/10.1046/j.1365-2133.2001.03956.x.
179. Weisblum B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585. http://dx.doi.org/10.1128 /AAC.39.3.577.
180. Kasimatis G, Fitz-Gibbon S, Tomida S, Wong M, Li H. 2013. Analysis of complete genomes of Propionibacterium acnes reveals a novel plasmid and increased pseudogenes in an acne associated strain. Biomed. Res. Int. 2013:918320. http://dx.doi.org/10.1155/2013/918320.
181. Furustrand Tafin U, Trampuz A, Corvec S. 2013. In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene. J. Antimicrob. Chemother. 68:523-528. http://dx.doi.org/10.1093/jac/dks428.
182. Tunney MM, Dunne N, Einarsson G, McDowell A, Kerr A, Patrick S. 2007. Biofilm formation by bacteria isolated from retrieved failed prosthetic hip. J. Orthop. Res. 25:2-10. http://dx.doi.org/10.1002/jor.20298.
183. Peel TN, Cheng AC, Choong PF, Buising KL. 2012. Early onset prosthetic hip and knee joint infection: treatment and outcomes in Victoria, Australia. J. Hosp. Infect. 82:248-253. http://dx.doi.org/10.1016/j.jhin.2012.09.005.
184. Farhad R, Roger PM, Albert C, Pelligri C, Touati C, Dellamonica P, Trojani C, Boileau P. 2010. Six weeks antibiotic therapy for all bone infections: results of a cohort study. Eur. J. Clin. Microbiol. Infect. Dis. 29:217-222. http://dx.doi.org/10.1007/s10096-009-0842-1.
185. Bernard L, Legout L, Zurcher-Pfund L, Stern R, Rohner P, Peter R, Assal M, Lew D, Hoffmeyer P, Uckay I. 2010. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J. Infect. 61:125-132. http://dx.doi.org/10.1016/j.jinf.2010.05.005.
186. Hsieh PH, Huang KC, Lee PC, Lee MS. 2009. Two-stage revision of infected hip arthroplasty using an antibiotic-loaded spacer: retrospective comparison between short-term and prolonged antibiotic therapy. J. Antimicrob. Chemother. 64:392-397. http://dx.doi.org/10.1093/jac /dkp177.
187. Puhto AP, Puhto T, Syrjala H. 2012. Short-course antibiotics for prosthetic joint infections treated with prosthesis retention. Clin. Microbiol. Infect. 18:1143-1148. http://dx.doi.org/10.1111/j.1469-0691.2011.03693.x.
188. Hegde V, Meredith DS, Kepler CK, Huang RC. 2012. Management of postoperative spinal infections. World J. Orthop. 3:182-189. http://dx.doi.org/10.5312/wjo.v3.i11.182.
189. Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, Le Moal G, Godet C, Mulleman D, Azais I, Becq-Giraudon B, Choutet P. 2007. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin. Arthritis Rheum. 36:269-277. http://dx.doi.org/10.1016/j.semarthrit.2006.09.004.
190. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus AM, Thilen U, Lekakis J, Lengyel M, Muller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL, ESC Committee for Practice Guidelines. 2009. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur. Heart J. 30:2369-2413. http://dx.doi.org/10.1093/eurheartj/ehp285.
191. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, Wilson WR, Beerman LB, Bolger AF, Estes NA, III, Gewitz M, Newburger JW, Schron EB, Taubert KA, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in Young, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care, American Heart Association. 2010. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121:458-477. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192665.
192. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724. http://dx.doi.org/10.1128/AAC.00047-09.
193. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148. http://dx.doi.org/10.1128/AAC.00775-08.
194. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541.
195. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR. 2010. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur. J. Clin. Microbiol. Infect. Dis. 29:961-967. http://dx.doi.org/10.1007/s10096-010-0952-9.
196. Barberan J, Aguilar L, Gimenez MJ, Carroquino G, Granizo JJ, Prieto J. 2008. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int. J. Antimicrob. Agents 32:154-157. http://dx.doi.org/10.1016 /j.ijantimicag.2008.03.003.
197. Berdal JE, Skramm I, Mowinckel P, Gulbrandsen P, Bjornholt JV. 2005. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin. Microbiol. Infect. 11:843-845. http://dx.doi.org /10.1111/j.1469-0691.2005.01230.x.
198. Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2011. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus. J. Infect. 63:229-235. http://dx.doi.org/10.1016/j.jinf.2011.07.001.
199. Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC. 2011. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:4589-4593. http://dx.doi.org/10.1128/AAC.00675-11.
200. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253. http://dx.doi.org/10.1093 /clinids/14.6.1251.
201. Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, Nuesch R, Zellweger C, Vogt M, Zimmerli W. 2013. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection 41:431-437. http://dx.doi.org/10.1007/s15010-012-0325-7.
202. Wehrli W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl 3):S407-S411.
203. Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X. 2005. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J. Antimicrob. Chemother. 56:1172-1175. http://dx.doi.org/10.1093/jac/dki364.
204. Sande MA, Mandell GL. 1975. Effect of rifampin on nasal carriage of Staphylococcus aureus. Antimicrob. Agents Chemother. 7:294-297. http://dx.doi.org/10.1128/AAC.7.3.294.
205. Topolski MS, Chin PY, Sperling JW, Cofield RH. 2006. Revision shoulder arthroplasty with positive intraoperative cultures: the value of preoperative studies and intraoperative histology. J. Shoulder Elbow Surg. 15:402-406. http://dx.doi.org/10.1016/j.jse.2005.10.001.
206. Jones M, Kishore MK, Redfern D. 2011. Propionibacterium acnes infection of the elbow. J. Shoulder Elbow Surg. 20:e22-e25. http://dx.doi.org /10.1016/j.jse.2011.02.016.
207. Noble RC, Overman SB. 1987. Propionibacterium acnes osteomyelitis: case report and review of the literature. J. Clin. Microbiol. 25:251-254.
208. Söderquist B, Holmberg A, Unemo M. 2010. Propionibacterium acnes as an etiological agent of arthroplastic and osteosynthetic infections-two cases with specific clinical presentation including formation of draining fistulae. Anaerobe 16:304-306. http://dx.doi.org/10.1016/j.anaerobe.2009.10.009.
209. Wang KW, Chang WN, Shih TY, Huang CR, Tsai NW, Chang CS, Chuang YC, Liliang PC, Su TM, Rau CS, Tsai YD, Cheng BC, Hung PL, Chang CJ, Lu CH. 2004. Infection of cerebrospinal fluid shunts: causative pathogens, clinical features, and outcomes. Jpn. J. Infect. Dis. 57:44-48. http://www0.nih.go.jp/JJID/57/44.pdf.
210. Forward KR, Fewer HD, Stiver HG. 1983. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J. Neurosurg. 59:389-394.
211. Arnell K, Cesarini K, Lagerqvist-Widh A, Wester T, Sjolin J. 2008. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with Propionibacterium acnes and with other bacteria. J. Neurosurg. Pediatr. 1:366-372. http://dx.doi.org/10.3171/PED/2008/1/5/366.
212. Desai A, Lollis SS, Missios S, Radwan T, Zuaro DE, Schwarzman JD, Duhaime AC. 2009. How long should cerebrospinal fluid cultures be held to detect shunt infections? J. Neurosurg. Pediatr. 4:184-189. http: //dx.doi.org/10.3171/2009.4.PEDS08279.
213. Bordes A, Elcuaz R, Noguera FJ, Otemin C, Egas G. 1997. Propionibacterium acnes infection in patients with CSF shunts. Enferm. Infecc. Microbiol. Clin. 15:24-27. (In Spanish.)
214. Thompson TP, Albright AL. 1998. Proprionibacterium [sic] acnes infections of cerebrospinal fluid shunts. Childs Nerv. Syst. 14:378-380. http: //dx.doi.org/10.1007/s003810050248.
215. Westergren H, Westergren V, Forsum U. 1997. Propionibacterium acnes in cultures from ventriculo-peritoneal shunts: infection or contamination? Acta Neurochir. (Wien) 139:33-36. http://dx.doi.org/10.1007 /BF01850865.
216. Pihl M, Davies JR, Johansson AC, Svensater G. 2013. Bacteria on catheters in patients undergoing peritoneal dialysis. Perit. Dial. Int. 33: 51-59. http://dx.doi.org/10.3747/pdi.2011.00320.
217. Noiri Y, Katsumoto T, Azakami H, Ebisu S. 2008. Effects of Er:YAG laser irradiation on biofilm-forming bacteria associated with endodontic pathogens in vitro. J. Endod. 34:826-829. http://dx.doi.org/10.1016/j.joen.2008.04.010.
218. Takemura N, Noiri Y, Ehara A, Kawahara T, Noguchi N, Ebisu S. 2004. Single species biofilm-forming ability of root canal isolates on gutta-percha points. Eur. J. Oral Sci. 112:523-529. http://dx.doi.org/10.1111 /j.1600-0722.2004.00165.x.
219. Debelian GJ, Olsen I, Tronstad L. 1992. Profiling of Propionibacterium acnes recovered from root canal and blood during and after endodontic treatment. Endod. Dent. Traumatol. 8:248-254. http://dx.doi.org/10.1111/j.1600-9657.1992.tb00253.x.
220. Fujii R, Saito Y, Tokura Y, Nakagawa KI, Okuda K, Ishihara K. 2009. Characterization of bacterial flora in persistent apical periodontitis lesions. Oral Microbiol. Immunol. 24:502-505. http://dx.doi.org/10.1111 /j.1399-302X.2009.00534.x.
221. Silva-Boghossian CM, Neves AB, Resende FA, Colombo AP. 2013. Suppuration-associated bacteria in subjects with chronic and aggressive periodontitis. J. Periodontol. 84:e9-e16. http://dx.doi.org/10.1902/jop.2013.120639.
222. Fritschi BZ, Albert-Kiszely A, Persson GR. 2008. Staphylococcus aureus and other bacteria in untreated periodontitis. J. Dent. Res. 87:589-593. http://dx.doi.org/10.1177/154405910808700605.
223. Coenye T, Honraet K, Rossel B, Nelis HJ. 2008. Biofilms in skin infections: Propionibacterium acnes and acne vulgaris. Infect. Disord. Drug Targets 8:156-159. http://dx.doi.org/10.2174/187152651080803 0156.
224. Mak TN, Fischer N, Laube B, Brinkmann V, Metruccio MM, Sfanos KS, Mollenkopf HJ, Meyer TF, Brüggemann H. 2012. Propionibacterium acnes host cell tropism contributes to vimentin-mediated invasion and induction of inflammation. Cell. Microbiol. 14:1720-1733. http: //dx.doi.org/10.1111/j.1462-5822.2012.01833.x.
225. Olsson J, Davidsson S, Unemo M, Mölling P, Andersson SO, Andren O, Söderquist B, Sellin M, Elgh F. 2012. Antibiotic susceptibility in prostate-derived Propionibacterium acnes isolates. APMIS 120:778-785. http://dx.doi.org/10.1111/j.1600-0463.2012.02905.x.
226. Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Brüggemann H, Nelson WG, De Marzo AM, Yegnasubramanian S, Sfanos KS. 2013. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate 73:1007-1015. http://dx.doi.org/10.1002/pros.22648.
227. Montero JA, Ruiz-Moreno JM, Rodriguez AE, Ferrer C, Sanchis E, Alio JL. 2006. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur. J. Ophthalmol. 16:343-345.
228. Ang M, Chee SP. 2010. Propionibacterium acnes endogenous endophthalmitis presenting with bilateral scleritis and uveitis. Eye (Lond.) 24: 944-945. http://dx.doi.org/10.1038/eye.2009.194.
229. Boase S, Foreman A, Cleland E, Tan L, Melton-Kreft R, Pant H, Hu FZ, Ehrlich GD, Wormald PJ. 2013. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biofilm detection. BMC Infect. Dis. 13:210. http://dx.doi.org/10.1186/1471-2334-13-210.
230. Kurokawa I, Nishijima S, Kawabata S. 1999. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur. J. Dermatol. 9:25-28.
231. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152. http://dx.doi.org/10.1128/AAC.48.6.2149-2152.2004.
232. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. 2008. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother. 52:761-766. http: //dx.doi.org/10.1128/AAC.01128-07.
233. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
234. Gonzalez R, Welsh O, Ocampo J, Hinojosa-Robles RM, Vera-Cabrera L, Delaney ML, Gomez M. 2010. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int. J. Dermatol. 49:1003-1007. http://dx.doi.org/10.1111/j.1365-4632.2010.04506.x.
235. Shames R, Satti F, Vellozzi EM, Smith MA. 2006. Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime. J. Clin. Microbiol. 44:4227-4228. http://dx.doi.org/10.1128/JCM.00722-06.
236. Nishijima S, Kurokawa I, Katoh N, Watanabe K. 2000. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J. Dermatol. 27:318-323.
237. Oprica C, Emtestam L, Lapins J, Borglund E, Nyberg F, Stenlund K, Lundeberg L, Sillerström E, Nord CE. 2004. Antibiotic-resistant Propionibacterium acnes on the skin of patients with moderate to severe acne in Stockholm. Anaerobe 10:155-164. http://dx.doi.org/10.1016/j.anaerobe.2004.02.002.
238. Song M, Seo SH, Ko HC, Oh CK, Kwon KS, Chang CL, Kim MB. 2011. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J. Dermatol. 38:667-673. http://dx.doi.org/10.1111/j.1346-8138.2010.01109.x.
239. Gubelin W, Martinez MA, Molina MT, Zapata S, Valenzuela ME. 2006. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne. Rev. Latinoam. Microbiol. 48:14-16. http://www.medigraphic.com/pdfs/lamicro/mi-2006/mi061d.pdf.
240. Snydman DR, Jacobus NV, McDermott LA. 2008. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob. Agents Chemother. 52:4492-4496. http://dx.doi.org /10.1128/AAC.00696-08.